GlyphAllo, a Novel, Orally Bioavailable Prodrug of Allopregnanolone, Induces an EEG Profile Consistent with GABAA Positive Allosteric Modulation in Healthy Volunteers
Monday, May 4, 2026 BiopharmaWatch Research 1 min read
Key Takeaway: GlyphAllo, an orally bioavailable prodrug of allopregnanolone, has shown an EEG profile indicative of GABAA positive allosteric modulation in healthy volunteers. This suggests potential therapeutic benefits in modulating GABAA receptors. The study results may pave the way for further exploration in clinical applications.
Price reaction · baseline $18.18 (2026-05-04T15:17:00.000Z) · hit during market hours · clean, no other SPTX news in the window
day 0 close
-6.5%
day 1
-12%
day 3 · peak
-14.7%
Market Sentiment Analysis
POSITIVE FACTORS
GlyphAllo shows promising EEG profile effects.
The prodrug demonstrates potential for GABAA modulation.
Healthy volunteers exhibited positive responses.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Cash runway
~12 mo
Low dilution risk
Lead asset
SPT-300
Phase 2 · Major Depressive Disorder (MDD)
Full Press Release Details
Home
Pipeline
Team
Research
NEWS
INVESTORS
Careers
Contact
Array - May 4, 2026
GlyphAllo, a Novel, Orally Bioavailable Prodrug of Allopregnanolone, Induces an EEG Profile Consistent with GABAA Positive Allosteric Modulation in Healthy Volunteers
Frequently Asked Questions
What is GlyphAllo?
GlyphAllo is a novel, orally bioavailable prodrug of allopregnanolone.
What effects did GlyphAllo have in the study?
GlyphAllo induced an EEG profile consistent with GABAA positive allosteric modulation.
Who participated in the GlyphAllo study?
The study involved healthy volunteers.
What is the significance of the EEG profile?
The EEG profile suggests potential therapeutic benefits in modulating GABAA receptors.